Particularly in GBM, the angiogenesis inhibitor bevacizumab has been shown to increase progression-free survival in patients with newly diagnosed or recurrent GBM, presumably by inhibiting both the formation of vessels dependent on VEGF and the vascular permeability of these highly vascular tumors [1, 33]. The gene discussed is VEGFA; the disease is glioblastoma.